GL1X · GenesisL1 explorer

MolNFT v1 · #141196 · protein

Crystal structure of mouse cytosolic isocitrate dehydrogenase

5YZH · Isocitrate dehydrogenase [NADP] cytoplasmic: “Crystal structure of mouse cytosolic isocitrate dehydrogenase”. X-ray diffraction, 1 ligand (NAP), 8 pockets (best druggability 0.80). MolNFT v1 #141196 on GenesisL1: 3D structure…

PDB
5YZH
Type
protein
Length
821 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Isocitrate dehydrogenase [NADP] cytoplasmic
EC
1.1.1.42
UniProt
O88844
Ligands
NAP
Pockets
8 · best druggability 0.80

Structure

x-ray diffraction · 2 distinct chains · 48% helix, 22% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AIsocitrate dehydrogenase [NADP] cytoplasmic (EC 1.1.1.42)protein41248% helix, 22% strandO88844
BIsocitrate dehydrogenase [NADP] cytoplasmic (EC 1.1.1.42)protein40948% helix, 22% strandO88844

Ligands and binding sites

  • NAP · Nadp nicotinamide-adenine-dinucleotide phosphate · ligand · 2 copies · chains A, B
  • GOL · Glycerol · additive · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

8 pockets found on a 1 Å grid, 2 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
110150.800.8291NAP
29120.790.8175NAP
3920.490.8219empty
41670.470.7620empty
51830.460.7422empty

Interfaces

1 interface between chains.

  • A–B · 3963 Ų buried · 71 hydrogen bonds · protein-protein

Compared structures

  • 5YZH · Crystal Structure of Mouse Cytosolic Isocitrate Dehydrogenase · the same entry in another collection · chain A against A, TM-score 1.00
  • O88844 · AlphaFold monomer V2.0 prediction for isocitrate dehydrogenase [NADP] cytoplasmic (O88844) · a predicted model of the same protein · chain B against A, TM-score 0.98

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.